Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-663-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The substance was assessed for oral and dermal acute toxicity. In the oral toxicity study, concentrations up to 10 g/kg bw were tested and the LD50 oral was determined being 6'176 mg/kg bw. The acute toxicity study by dermal route was performed as a limit test with only one dose of 2'000 mg/kg bw applied, showing no mortality to any of the animals (5 males and 5 females) tested.
Thus, the substance is not subject to classification for acute oral or dermal toxicity according to CLP.
Data for acute inhalation toxicity are not required as the substance is not used as aerosol and due to the low vapour pressure of 0.000045 Pa no relevant vapour exposure is possible.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1973
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Groups of 4 albino rats (2 male, 2 female) were administered the test material by gavage at doses of approx. 3, 4.5, 7 and 10 g/kg bw (25% w/v Diacid in corn oil). After treatment, the animals were observed for 14 days for clinical signs. Body weights were measured at start and end of the observation period. Necropsy was performed on all animals.
- GLP compliance:
- no
- Remarks:
- study performed prior to GLP
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: ARS/Sprague-Dawley, Madison, Wisconsin.
- Age at study initiation: Young rats, no exact age available
- Weight at study initiation: 157 - 191 g
- Fasting period before study: 16 hours
- Housing: Stock cages
- Diet (e.g. ad libitum): Ad libitum, standard laboratory diet
- Water (e.g. ad libitum): Ad libitum, standard water
- Acclimation period: Five days under observation
ENVIRONMENTAL CONDITIONS
No data available - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 25% w/v
- Amount of vehicle (if gavage): varying per dose group (increased volume for higher dose)
- Justification for choice of vehicle: generally used vehicle
- Purity: No data available - Doses:
- - 3,038 mg/kg bw
- 4,556 mg/kg bw
- 6,834 mg/kg bw
- 10,250 mg/kg bw - No. of animals per sex per dose:
- 2
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations continuously, weights: initial and final (14 days)
- Necropsy of survivors performed: Yes
- Other examinations performed: clinical signs, body weight, necropsy of animals that died during the observation period - Statistics:
- The acute oral median lethal dose (LD50) was calculated using interpolation methods described by Weil (1952), Thompson (1947) and Thompson and Weil (1952).
- Preliminary study:
- Not relevant
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 6 176 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- > 5 548.9 - <= 6 803.1
- Remarks on result:
- other: SD of LD50: ±627.1 mg/kg
- Mortality:
- No mortality occurred in the two test groups receiving the lowest doses. 3 out of 4 deaths and 4 out of 4 deaths occurred in the 6834 and 10250 mg/kg bw groups during the 14 day observation period, respectively. Deaths occurred within 3 days in all cases.
- Clinical signs:
- Hypoactivity, ruffed fur, labored breathing, muscular weakness and diuresis were noted throughout the test groups. Labored breathing was not noted in the low dose group, while muscular weakness and diuresis were only observed in the two highest dose groups. The increase in clinical signs was dose-related.
- Body weight:
- Body weights of male and female animals were comparable throughout the groups at the start and end of the study. No statistical analysis was performed.
- Gross pathology:
- Necropsy examination of the animals that died revealed gastroenteritis. No gross pathologic alterations were noted among the surviving animals.
- Other findings:
- No data available.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- In this study the acute oral toxicity potential of Diacid 1550 was tested in rats by administration of doses varying from 3 to 10 g/kg bw by gavage. The acute oral LD50 was established to be 6176 mg/kg bw and therefore, the substance is not considered acute toxic via the oral route and does not have to be classified in accordance with the criteria outlined in Annex VI of 67/548/EEC and Annex I of 1272/2008/EC.
- Executive summary:
Groups of 4 albino rats (2 male, 2 female) were administered by gavage the test material at doses of approx. 3, 4.5, 7 and 10 g/kg bw (25% w/v Diacid in corn oil). After treatment, the animals were observed for 14 days for clinical signs. Body weights were measured at start and end of the observation period. Necropsy was performed on all animals.
No mortality occurred in the two test groups receiving the lowest doses. 3 out of 4 deaths and 4 out of 4 deaths occurred in the 6834 and 10250 mg/kg bw groups during the 14 day observation period, respectively. Deaths occurred within 3 days in all cases. Hypoactivity, ruffed fur, labored breathing, muscular weakness and diuresis were noted throughout the test groups. Labored breathing was not noted in the low dose group, while muscular weakness and diuresis were only observed in the two highest dose groups. The increase in clinical signs was dose-related. Body weights of male and female animals were comparable throughout the groups at the start and end of the study. No statistical analysis was performed. Necropsy examination of the animals that died revealed gastroenteritis. No gross pathologic alterations were noted among the surviving animals.
The acute oral LD50 was established to be 6176 mg/kg bw and therefore, the substance is not considered acute toxic via the oral route.
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Read across to study on source substance
- Justification for type of information:
- 1. HYPOTHESIS FOR THE ANALOGUE APPROACH
The main assumption for this read across approach is that the source substance fatty acids, tall-oil, reaction product with acrylic acid and the target substance fatty acids, tall-oil, reaction product with acrylic acid, potassium salt have a common organic moiety, the anion of the salt.
In fact, the target substance “fatty acids, tall-oil, reaction product with acrylic acid, potassium salt” is the potassium salt of its parent acid “fatty acids, tall-oil, reaction product with acrylic acid”.
In aqueous media, the target substance rapidly dissociates in its parent acid anion and potassium cation.
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
The fatty acids, tall-oil, reaction product with acrylic acid (EC 939-424-4) is a UVCB substance in its own right and therefore, of 100 % purity. This substance is neutralized by potassium hydroxide; CAS 1310-58-3; EC 215-181-3; as 45 % aqueous solution.
3. ANALOGUE APPROACH JUSTIFICATION
A reliable acute toxicity study is available for the source substance fatty acids, tall-oil, reaction product with acrylic acid, showing that the substance is not acute toxic via the oral route (LD 50 = 6176 mg/kg).
Since the target and the source substance dissociate to the same anion and potassium (cation) is known to be non-toxic, both, target and read-across substance, do share the same toxicological mechanisms, and the effects of the target substance is predicted to be equal to the effects of the source substance.
The common compound fatty acids, tall-oil, reaction product with acrylic acid is solely responsible for the absence or presence of effects.
The toxicity of potassium cation is assumed to be largely irrelevant in producing any effects to be assessed.
In fact, according to the EFSA opinion of the Scientific Panel on dietetic products, Nutrition and Allergies on a request from the commission related to the Tolerable Upper Intake Level of Potassium, potassium is not classified as acute toxic via the oral route. - Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Groups of 4 albino rats (2 male, 2 female) were administered the test material by gavage at doses of approx. 3, 4.5, 7 and 10 g/kg bw (25% w/v Diacid in corn oil). After treatment the animals were observed for 14 days for clinical signs. Body weights were measured at start and end of the observation period. Necropsy was performed on all animals.
- GLP compliance:
- no
- Remarks:
- test performed prior to GLP
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 6 176 mg/kg bw
- Based on:
- test mat.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- In this study the acute oral toxicity potential of Diacid 1550 was tested in rats by administration of doses varying from 3 to 10 g/kg bw by gavage. The acute oral LD50 was established to be 6176 mg/kg bw and therefore, the substance is not considered acute toxic via the oral route. As the tested substance Diacid 1550 and the traget substance Diacid 1550 potassium salt do share the same organic moity, only distinguishing by the potassium cation, the results form this study is applicable to the potassium salt too.
Referenceopen allclose all
Clinical signs
Dose (mg/kg bw) | Reaction | Time of onset after dose administration | Duration of reaction |
3038 | Hypoactivity | 1 hour | 1 day |
Ruffed fur | 1 hour | 1 day | |
4556 | Hypoactivity | 1 hour | 2 days |
Ruffed fur | 1 hour | 2 days | |
Labored breathing | 3 hours | 6-22 hours | |
6834 | Hypoactivity | 1 hour | 5 days |
Ruffed fur | 1 hour | 5 days | |
Labored breathing | 2 hours | 2 days | |
Muscular weakness | 3 hours | 2 days | |
Diuresis | 6-22 hours | 2 days | |
10250 | Hypoactivity | 1 hour | Until death |
Ruffed fur | 1 hour | ||
Labored breathing | 2 hours | ||
Muscular weakness | 3 hours | ||
Diuresis | 6-22 hours |
Body weights
Dose (mg/kg bw) | Animal | Body weight (grams) | |
Initial | Final | ||
3038 | 1-M | 173 | 274 |
2-M | 157 | 258 | |
3-F | 163 | 215 | |
4-F | 164 | 220 | |
4556 | 5-M | 163 | 286 |
6-M | 168 | 286 | |
7-F | 171 | 224 | |
8-F | 190 | 226 | |
6834 | 9-M | 164 | - |
10-M | 163 | 277 | |
11-F | 185 | - | |
12-F | 183 | - | |
10250 | 13-M | 160 | - |
14-M | 174 | - | |
15-F | 191 | - | |
16-F | 176 | - |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 6 176 mg/kg bw
- Quality of whole database:
- The acute oral toxicity potential of Diacid 1550 was tested in rats by administration of doses varying from 3 to 10 g/kg bw by gavage. The acute oral LD50 was established to be 6176 mg/kg bw and therefore the substance is not considered acute toxic via the oral route. As the organic moiety is decisive for toxicity (not the potassium cation), this result is representative for the corresponding potassium salt too.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- April -September 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- Identification: H-240 100% a.s.
Synonyms: Diacid H-240; OCD 9142-055
CAS Number: 68127-33-3
Purity: 100%
Physical state/Appearance: amber colored solid
Expiry Date: 10 April 2018
Storage Conditions: room temperature in the dark - Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Five male and five female Wistar (RccHanTm:WIST) strain rats were supplied by Envigo RMS (UK) Limited, Oxon, UK. On receipt the animals were randomly allocated to cages. The females were nulliparous and non-pregnant. After an acclimatization period of at least 5 days the animals were selected at random and given a number unique within the study by indelible ink-marking on the tail and a number written on a cage card. At the start of the study the animals weighed at least 200 g, and were 8 to 12 weeks of age. The weight variation did not exceed ±20% of the mean weight for each sex.
The animals were housed in suspended solid floor polypropylene cages furnished with woodflakes. The initial two animals were housed individually throughout the study. The further group of eight animals (four male and four female) were housed individually during the 24-hour exposure period and in groups of four, by sex, for the remainder of the study. Free access to mains drinking water and food (2014C Teklad Global Rodent diet supplied by Envigo RMS (UK) Limited, Oxon, UK) was allowed throughout the study.
The diet, drinking water and bedding were routinely analyzed and were considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study.
The temperature and relative humidity were set to achieve limits of 19 to 25 °C and 30 to 70%, respectively. The rate of air exchange was at least fifteen changes per hour and the lighting was controlled by a time switch to give 12 hours continuous light and 12 hours darkness.
The animals were provided with environmental enrichment items which were considered not to contain any contaminant of a level that might have affected the purpose or integrity of the study. - Type of coverage:
- semiocclusive
- Vehicle:
- other: For the purpose of the study the test item was weighed out according to each animal's individual body weight and moistened with distilled water prior to application.
- Duration of exposure:
- 24 h
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- 5 males (2000 mg/kg), 5 females (2000 mg/kg)
- Control animals:
- no
- Details on study design:
- On the day before treatment the back and flanks of each animal were clipped free of hair.
In the absence of data suggesting the test item was toxic, one male and one female rat were initially treated with the test item at a dose level of 2000 mg/kg.
The appropriate amount of test item, moistened with distilled water, was applied as evenly as possible to an area of shorn skin (approximately 10% of the total body surface area). A piece of surgical gauze was placed over the treatment area and semi-occluded with a piece of self-adhesive bandage. The animals were caged individually throughout the study. Shortly after dosing the dressings were examined to ensure that they were securely in place.
After the 24-hour contact period the bandage was carefully removed and the treated skin and surrounding hair wiped with cotton wool moistened with distilled water to remove any residual test item.
As no mortalities were noted a further group of animals (four males and four females) was similarly treated with the test item at a dose level of 2000 mg/kg body weight to give a total of five males and five females. The animals were caged individually for the 24-hour exposure period. After the 24-hour contact period the bandages were carefully removed and the treated skin and surrounding hair wiped with cotton wool moistened with distilled water to remove any residual test item. These animals were returned to group housing for the remainder of the test period.
The animals were observed for deaths or overt signs of toxicity 30 minutes, 1, 2 and 4 hours after dosing and subsequently once daily for 14 days.
After removal of the dressings and subsequently once daily for 14 days, the test sites were examined for evidence of primary irritation and scored according to the following scale:
EVALUATION OF SKIN REACTIONS
Erythema and Eschar Formation
Value
No erythema 0
Very slight erythema (barely perceptible) 1
Well-defined erythema 2
Moderate to severe erythema 3
Severe erythema (beef redness) to slight eschar formation (injuries in depth) 4
Edema Formation
No edema 0
Very slight edema (barely perceptible) 1
Slight edema (edges of area well-defined by definite raising) 2
Moderate edema (raised approximately 1 millimeter) 3
Severe edema (raised more than 1 millimeter and extending beyond the area of exposure) 4
Any other skin reactions, if present were also recorded.
Individual body weights were recorded prior to application of the test item on Day 0 and on Days 7 and 14.
At the end of the study the animals were killed by cervical dislocation. All animals were subjected to gross necropsy. This consisted of an external examination and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded. No tissues were retained. - Statistics:
- The following computerized system was used in the study:
Delta Controls — ORCAview - Preliminary study:
- Initially, two animals (one male and one female) were given a single, 24 hour, semi-occluded dermal application of the test item to intact skin at a dose level of 2000 mg/kg body weight. As no mortalities were noted a further group of animals (four males and four females) was similarly treated with the test item at a dose level of 2000 mg/kg body weight to give a total of five males and five females.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There were no deaths
- Clinical signs:
- No signs of systemic toxicity were noted during the observation period
- Body weight:
- One female showed no gain in body weight during the first week with expected gain in body weight during the second week and one other female showed expected gain in body weight during the first week but body weight loss during the second week. The remaining animals showed expected gains in body weight over the study period.
- Gross pathology:
- No abnormalities were noted at necropsy
- Other findings:
- Dermal reactions: Very slight or well-defined erythema and very slight or slight edema were noted at the test sites of all animals. Hemorrhage of dermal capillaries and/or small superficial scattered scabs were noted at the test sites of three animals. Scab cracking was also noted at the test site of one male. Loss of skin elasticity and flexibility was noted at the test sites of two males.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg body weight.
- Executive summary:
The study was performed to assess the acute dermal toxicity of the test item in the Wistar strain rat.
Methods
Initially, two animals (one male and one female) were given a single, 24 hour, semi-occluded dermal application of the test item to intact skin at a dose level of 2000 mg/kg body weight. Based on the results of the initial test, a further group of eight animals (four males and four females) was equally treated. Clinical signs and body weight development were monitored during the study. All animals were subjected to gross necropsy.
Results
Mortality. There were no deaths.
Clinical Observations. There were no signs of systemic toxicity.
Dermal Irritation. Signs of dermal irritation noted were very slight to well-defined erythema, very slight to slight edema, hemorrhage of dermal capillaries, loss of skin elasticity and flexibility, small superficial scattered scabs and scab cracking.
Body Weight. One female showed no gain in body weight during the first week with expected gain in body weight during the second week and one other female showed expected gain in body weight during the first week but body weight loss during the second week. The remaining animals showed expected gains in body weight over the study period.
Necropsy. No abnormalities were noted at necropsy.
ConclusionThe acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg body weight. Dermal irritation was low and below threshold for classification. Furthermore, all dermal irritation scores reduced over time, showing the effects being fully reversible.
Reference
Individual clinical observations and mortality data
Dose |
Animal |
Effects Noted After Dosing |
Effects Noted During Period After Dosing (Days) |
||||||||||||||||
Y2 |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
2000 |
1-0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3-0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2-0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
4-0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
4-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
4-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
4-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = No signs of systemic toxicity
Individual Dermal Reactions - Males
Dose Level mg/kg |
Animal |
Observation |
Effects Noted After Initiation of Exposure (Days) |
|||||||||||||
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||
2000 |
1-0 |
Erythema |
2 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Edema |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
3-0 |
Erythema |
2 |
2 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
2 |
2 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
Hd |
Ss |
Ss |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
3-1 |
Erythema |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
LeLf |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
3-2 |
Erythema |
2 |
2 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
2 |
2 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
Ss |
SsSk |
Ss |
Ss |
Ss |
Ss |
Ss |
0 |
0 |
0 |
0 |
0 |
||
3-3 |
Erythema |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
LeLf |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = No reactions
Hd = Hemorrhage of dermal capillaries
Ss = Small superficial scattered scabs
0 = Due to a technician error observation not recorded
Individual Dermal Reactions - Females
Dose Level mg/kg |
Animal |
Observation |
Effects Noted After Initiation of Exposure (Days) |
|||||||||||||
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||
2000 |
2-0 |
Erythema |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Edema |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
4-0 |
Erythema |
2 |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
2 |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
Hd |
Ss |
Ss |
Ss |
Ss |
Ss |
Ss |
Ss |
0 |
0 |
0 |
0 |
0 |
||
4-1 |
Erythema |
2 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
4-2 |
Erythema |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
4-3 |
Erythema |
2 |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Edema |
2 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = No reactions
Hd = Hemorrhage of dermal capillaries
Ss = Small superficial scattered scabs
0 = Due to a technician error observation not recorded
Individual Body Weights and Body Weight Changes
Dose Level |
Animal Number |
Body Weight (g) at Day |
Body Weight Change (g) During Week |
|||
0 |
7 |
14 |
1 |
2 |
||
2000 |
1-0 Male |
260 |
282 |
319 |
22 |
37 |
3-0 Male |
287 |
306 |
326 |
19 |
20 |
|
3-1 Male |
281 |
303 |
320 |
22 |
17 |
|
3-2 Male |
284 |
305 |
328 |
21 |
23 |
|
3-3 Male |
269 |
284 |
302 |
15 |
18 |
|
2-0 Female |
222 |
250 |
245 |
28 |
—5 |
|
4-0 Female |
234 |
235 |
247 |
1 |
12 |
|
4-1 Female |
228 |
228 |
238 |
0 |
10 |
|
4-2 Female |
230 |
241 |
257 |
11 |
16 |
|
4-3 Female |
225 |
230 |
241 |
5 |
11 |
Individual Necropsy Findings
Dose Level |
Animal Number |
Time of Death |
Macroscopic Observations |
2000 |
1-0 |
Killed Day 14 |
No abnormalities detected |
3-0 |
Killed Day 14 |
No abnormalities detected |
|
3-1 |
Killed Day 14 |
No abnormalities detected |
|
3-2 |
Killed Day 14 |
No abnormalities detected |
|
3-3 |
Killed Day 14 |
No abnormalities detected |
|
2-0 |
Killed Day 14 |
No abnormalities detected |
|
4-0 |
Killed Day 14 |
No abnormalities detected |
|
4-1 |
Killed Day 14 |
No abnormalities detected |
|
4-2 |
Killed Day 14 |
No abnormalities detected |
|
4-3 |
Killed Day 14 |
No abnormalities detected |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
Additional information
The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg body weight.
Justification for classification or non-classification
Based on acute oral and dermal toxicity test results, the substance was shown not to be subject to classification according to CLP (Regulation EC No. 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.